Bacalo
07/05/26 18:05
Ha respondido al tema
Grifols (GRF): siguiendo de cerca la acción
Biopharma revenues increased 6.8% cc . The IG franchise grew 15.3% cc Albumin declined 6.1% cc Alpha-1 and Specialty proteins declined 7.4% Dependiendo cada vez más de las inmunoglobulinas no es posible mejorar el margen, se la juegan al plasma barato de Egipto: The Egypt project .... . Beyond adding capacity, it is expected to structurally improve margin expansion over time . Between 2025 and 2029, ex-U.S. plasma supply is expected to more than double, driven largely by Egypt. This rebalancing is expected to enhance plasma economics, support mid- to high-single digit growth in ex-U.S. supply, strengthen supply resilience and contribute to a structurally improved margin profile